News
- November 27, 2019
- Announcement of listing on the NHI drug price standard and marketing of Teribone™ 28.2 µg subcutaneous autoinjector
- November 25, 2019
- Asahi Kasei to Acquire Veloxis Pharmaceuticals Inc.
- November 25, 2019
- Asahi Kasei Pharma licenses fasudil to Woolsey Pharmaceuticals
- October 30, 2019
- Asahi Kasei Pharma to solicit proposals for drug discovery research
- October 1, 2019
- Filing of Complaint for Injunctive Relief requesting for continuous supply of "XIAFLEX® injection"
- September 20, 2019
- Approval to manufacture and sell Teribone™ autoinjector
- August 2, 2019
- Future plan for global Phase III clinical study of ART-123
- February 21, 2019
- Maruho and Asahi Kasei Pharma Announce First Approval in Japan of an Additional Dosage and Administration for Anti-herpes Virus Agent "Famvir® Tab 250 mg" for the Treatment of Recurrent Herpes Simplex (Herpes labialis/Herpes genitalis)
- January 28, 2019
- Asahi Kasei Pharma launching legionella kit Ribotest™ Legionella